Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 976 to 1000 of 2013

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Urinary incontinence and pelvic organ prolapse in women: managementNG123
Ambu aScope4 Broncho for use in unexpected difficult airwaysHTG312
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVIHTG515
Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the legHTG516
Bronchoscopic thermal vapour ablation for upper-lobe emphysemaHTG517
Endocuff Vision for assisting visualisation during colonoscopyHTG514
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central cathetersHTG368
Percutaneous mitral valve leaflet repair for mitral regurgitationHTG513
Therapeutic hypothermia for acute ischaemic strokeHTG511
Collagen paste for closing an anal fistulaHTG512
Hyperparathyroidism (primary): diagnosis, assessment and initial managementNG132
Inotersen for treating hereditary transthyretin amyloidosisHST9
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Curos for preventing infections when using needleless connectorsHTG510
Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary careHTG508
Ulcerative colitis: managementNG130
Crohn's disease: managementNG129
Intrapartum care for women with existing medical conditions or obstetric complications and their babiesNG121
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576

Results per page

  1. 10
  2. 25
  3. 50
  4. All